In the three studies, from a mean baseline body weight of 75.3 kg, 73.3 kg, and 76.6 kg, respectively, after randomization there were corresponding mean reductions of 0.8 kg, 1.6 kg, and 1.3 kg (60 mcg TID) and 0.8 kg (60 mcg QID) in the SYMLIN treatment group compared to mean increases of +0.8 kg, +0.4 kg, and +0.7 kg in the placebo treatment group
The SURMOUNT-2 trial (2023) focused specifically on patients with type 2 diabetes and obesity, demonstrating average weight loss of 14.7% at the 15 mg dose, a substantial improvement over prior GLP-1 monotherapy results in this population
Therefore, breastfeeding is generally not advised while receiving sermorelin, or the drug should be used only if clearly needed and if the mothers healthcare provider determines that the benefits outweigh the potential risks to the infant
What GLP-1 actually costs in Pennsylvania without insurance For a cash-pay PA resident with no GLP-1 coverage, the real annual numbers come down to dose tier and medication source
This demonstrates the difficulties of comparing different studies with different experimental protocols involving different populations consuming different diets
